Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

National Glaucoma Research - Completed Award

Photo Pending

Kathryn Bollinger, M.D.

The Cleveland Clinic Foundation
Cleveland, OH

Title: Glaucoma Biomarker Discovery and Pathogenetics
Non-Technical Title: Developing early diagnosis strategies

Duration: April 1, 2007 - June 30, 2009
Award Type: Standard
Award Amount: $90,000


Summary:

We will use mass spectrometry to identify biomarkers in blood samples from individuals with POAG. These biomarkers will be analyzed to ensure they are specific to glaucoma and hence useful for the development of diagnostic tests and new drugs.

Details:

Glaucoma is a group of eye diseases that damages the optic nerve and result in blindness if left untreated. The most common form is primary open-angle glaucoma (POAG). POAG affects over 3 million Americans, a majority of whom do not know they have it. There is currently no cure for glaucoma. We believe that molecular markers exist in the blood of individuals susceptible to developing glaucoma. These molecules are small fragments of proteins that arise from breakdown of proteins during normal cellular functions in the body. Sometimes the levels of certain molecules in the blood change when a person gets sick. The identification of these molecular markers or 'biomarkers' will let doctors identify those at risk before clinical evidence of the disease. More importantly, these biomarkers could lead to new therapies for glaucoma. We will use instruments known as mass spectrometers to identify biomarkers in blood samples from individuals with POAG. These biomarkers will be analyzed to ensure they are specific to glaucoma and hence useful for the development of diagnostic tests and new drugs. The long term goals of our research are to develop 1) a blood test for early detection and 2) new treatments for this debilitating disease.